Pathogenic bone loss in rheumatoid arthritis: Mechanisms and therapeutic approaches

Melissa D. Cantley, Malcolm D. Smith, David R. Haynes

Research output: Contribution to journalReview articlepeer-review

13 Citations (Scopus)


Rheumatoid arthritis (RA) is a systemic inflammatory disorder with progressive joint destruction being its hallmark feature. Conventional treatments, such as DMARDs, aim to inhibit the inflammation; however, over the past decade, major advances in our understanding of bone metabolism has given us the ability to directly treat the bone loss in RA. Although modern anti-inflammatory therapies, such as anti-TNF-α treatment, have resulted in a remarkable improvement in the treatment of RA, these treatments do not directly target bone destruction in the joint. The aim of this review is to demonstrate that antiresorptive therapies can prevent structural joint destruction, particularly in the early stages of anti-inflammatory treatment. A number of novel approaches targeting bone resorption are also becoming available.

Original languageEnglish
Pages (from-to)561-582
Number of pages22
JournalInternational Journal of Clinical Rheumatology
Issue number5
Publication statusPublished - 2009
Externally publishedYes


  • Anti-inflammatory treatments
  • Antiresorptive treatments
  • B ligand
  • NFATc1
  • Nuclear factor of activated T cells
  • Osteoclasts receptor activator of nuclear factor
  • Rheumatoid arthritis


Dive into the research topics of 'Pathogenic bone loss in rheumatoid arthritis: Mechanisms and therapeutic approaches'. Together they form a unique fingerprint.

Cite this